VANCOUVER, Jan. 30, 2017 /PRNewswire/ - Alternate Health Corp.(CSE:AHG) (the "Company") is pleased to announce the first continuing medical education course on the "Endocannabinoid System and Cannabidiol." The course is accredited through the University of Louisville in accordance with the American Medical Association (AMA) and the American Board of Medical Specialties (ABMS) educational requirements, and provides a comprehensive overview of the endocannabinoid system (ECS), and the vital role it plays in various physiological functions of the human body.
"Doctors and medical professionals have been waiting for a proper medical education program to provide details for this emerging medicine," said Jim Griffiths, CFO for Alternate Health. This program is the culmination of many years of investigation and research, coupled with a substantial investment in production to create a quality and esthetically pleasing education program for Doctors and healthcare practitioners."
In order to demonstrate the quality and comprehensive nature of this program, Alternate Health have included a complimentary sample (https://youtu.be/uUl3kTg_6QQ) of the endocannabinoid course, and will commence sales of the online course on our website (www.alternatemedical.com) and at events across the United States and Canada.
The Company has formed a wholly-owned subsidiary called Alternate Medical Media, LLC ("AMM") and this course will be an important asset in creating the means for attracting and effectively communicating with the Company's targeted audience. AMM's services are distinctive in utilizing advanced media techniques to effectively communicate complex information and introduce new, innovative and emerging diagnostics, treatments and non-traditional solutions.
"This course, and the ones we currently have in development are a breakthrough in the digital medical education industry in that they combine the most current graphics and technology" said Rick Anderson, Managing Director for Alternate Medical Media. "I've been working in the CME [continuing medical education] space for many years and when I show our new course to my institutional contacts they are all truly amazed by what they see."
According to annual data from the ACCME, continuing medical education is currently a $2.6 billion industry. AMM will launch the endocannabinoid course this week, selling for $399 with practitioners receiving full credits for its completion.
Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.
On behalf of the Board of Directors of ALTERNATE HEALTH CORP. "Jim Griffiths" Director and CFO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.